Get the Stockscreener App
0.893
1.48%
0.013
Context Therapeutics Inc stock is traded at $0.893, with a volume of 86,575.
It is up +1.48% in the last 24 hours and up +7.95% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$0.88
Open:
$0.91
24h Volume:
86,575
Relative Volume:
0.35
Market Cap:
$80.11M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.9813
EPS:
-0.91
Net Cash Flow:
$-31.63M
1W Performance:
+13.57%
1M Performance:
+7.95%
6M Performance:
+9.71%
1Y Performance:
-64.28%
1-Day Range:
$0.8587
$0.91
1-Week Range:
$0.7864
$0.94
52-Week Range:
$0.49
$2.62
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.893 | 78.25M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
Does Context Therapeutics Inc. qualify in momentum factor screening2025 Market Sentiment & Short-Term High Return Ideas - Newser
Will Context Therapeutics Inc. stock recover after recent drop2025 Bull vs Bear & Short-Term Trading Alerts - Newser
How to use a screener to detect Context Therapeutics Inc. breakoutsRecession Risk & Real-Time Market Trend Scan - Newser
What analysts say about Context Therapeutics Inc. stock outlookWeekly Investment Summary & Fast Entry High Yield Stock Tips - Newser
Is this a good reentry point in Context Therapeutics Inc.Weekly Profit Summary & Stepwise Trade Execution Plans - Newser
Earnings visualization tools for Context Therapeutics Inc.July 2025 Rallies & AI Powered Buy and Sell Recommendations - Newser
Best data tools to analyze Context Therapeutics Inc. stock2025 Earnings Surprises & Real-Time Volume Trigger Notifications - Newser
Context Therapeutics Reports 2024 Results and Outlines Clinical Advancements - MSN
What to do if you’re stuck in Context Therapeutics Inc.2025 Analyst Calls & Fast Entry High Yield Stock Tips - Newser
Is it time to cut losses on Context Therapeutics IncMarket Trend Report & Verified High Yield Trade Plans - Newser
Is it time to cut losses on Context Therapeutics Inc.Buy Signal & Free Accurate Trade Setup Notifications - Newser
Visual analytics tools that track Context Therapeutics Inc. performanceWeekly Profit Recap & Verified Momentum Watchlists - Newser
Does Context Therapeutics Inc. have pricing powerJuly 2025 Recap & Daily Volume Surge Trade Alerts - newsyoung.net
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.25 Average Price Target from Analysts - Defense World
Quantitative breakdown of Context Therapeutics Inc. recent moveJuly 2025 Action & Daily Profit Focused Stock Screening - Newser
Machine Learning Models Forecast Context Therapeutics Inc. UptickEarnings Overview Summary & Fast Gain Stock Trading Tips - sundaytimes.kr
Applying sector rotation models to Context Therapeutics Inc.Trade Risk Summary & Fast Moving Stock Watchlists - Newser
Is Context Therapeutics Inc. stock showing strong momentum2025 Institutional Moves & Daily Oversold Bounce Ideas - sundaytimes.kr
Tools to monitor Context Therapeutics Inc. recovery probabilityQuarterly Portfolio Review & High Conviction Trade Alerts - Newser
What makes Context Therapeutics Inc. stock price move sharplyWeekly Profit Recap & Capital Efficiency Focused Ideas - Newser
How Context Therapeutics Inc. stock performs during market volatilityQuarterly Performance Summary & High Yield Equity Trading Tips - Newser
Context Therapeutics Inc. Facing Inflection Point in Trend AnalysisPortfolio Gains Report & Scalable Portfolio Growth Methods - newsyoung.net
How sentiment analysis helps forecast Context Therapeutics Inc.Weekly Trade Report & AI Enhanced Market Trend Forecasts - Newser
Detecting support and resistance levels for Context Therapeutics Inc.2025 Analyst Calls & Daily Technical Forecast Reports - Newser
Resistance Break Could Fuel Context Therapeutics Inc. Rally2025 Winners & Losers & Verified Chart Pattern Trade Signals - kangso.co.kr
Context Therapeutics Inc. shares rise 4.62% intraday as cancer treatment stocks surge. - AInvest
Can Context Therapeutics Inc. stock outperform in a bear marketJuly 2025 Rallies & Risk Controlled Daily Trade Plans - 선데이타임즈
Why Context Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 Macro Moves & Weekly Consistent Profit Watchlists - Newser
Sector ETF Data Correlates with Strength in Context Therapeutics Inc.2025 Performance Recap & Low Risk Investment Opportunities - beatles.ru
Context Therapeutics Inc. shares rise 1.90% after-hours as cancer treatment stocks surge. - AInvest
Full technical analysis of Context Therapeutics Inc. stockPortfolio Risk Summary & Daily Volume Surge Signals - Newser
Analyzing net buyer seller activity in Context Therapeutics Inc.2025 Trade Ideas & Real-Time Stock Movement Alerts - Newser
What technical models suggest about Context Therapeutics Inc.’s comebackRate Cut & Weekly Chart Analysis and Trade Guides - Newser
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Context Therapeutics Inc Stock (CNTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):